Deputy Attorney General Todd Blanche is accused of blocking the release of an unredacted report on a recently revealed drug trafficking and money laundering investigationDeputy Attorney General Todd Blanche is accused of blocking the release of an unredacted report on a recently revealed drug trafficking and money laundering investigation

Trump lawyer accused of 'stunning interference' to hide Epstein info: 'This reeks'

2026/03/19 00:18
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Deputy Attorney General Todd Blanche is accused of blocking the release of an unredacted report on a recently revealed drug trafficking and money laundering investigation into Jeffrey Epstein.

Sen. Ron Wyden (D-OR), in a letter to Blanche, called on the deputy attorney general to turn over a 69-page target profile prepared for the Drug Enforcement Administration by the Department of Justice's now-shuttered Organized Crime Drug Enforcement Task Forces as part of the congressionally mandated release of the Epstein files, reported Bloomberg.

“According to a confidential tip received by my staff, DEA Administrator Terry Cole was ready to provide an unredacted copy of the memorandum, but you stepped in to prevent him from doing so,” Wyden wrote. “Your alleged interference in this matter is highly disturbing.”

Wyden first asked for the document from the DEA on Feb. 25 when the years-long probe was first reported, but he said President Donald Trump's DOJ intervened.

“Shortly after I requested an unredacted copy of this OCDETF memorandum, DOJ stepped in to prevent DEA from complying with my request," Wyden wrote.

Bloomberg initially reported the DEA had opened the investigation into Epstein and a dozen other individuals in 2015 as part of a longstanding probe into organized crime, although none of the targets were charged with any crimes and it's not clear how long the case remained open.

An informant told authorities that Epstein was involved in the funding and distribution of club drugs like ecstasy and ketamine, as well as procuring Eastern European prostitutes for high-profile clients, and the target profile listed 12 other individuals and two businesses who sources identified as Epstein’s brother, accountants, attorneys and European women who worked as his assistants or fashion models.

No charges were ever filed in that case, and Mark Epstein and others contacted by Bloomberg said they had not been aware of the probe.

Wyden followed his letter with a tweet.

"This is stunning interference," he wrote. "The document I’m after literally says 'unclassified' at the top. The investigation it details is closed. Given Blanche's close personal ties to Donald Trump, this reeks of a continued coverup to protect key names in the Trump administration."

Wyden noted in his letter that he has been “following the money and examining the extent to which Epstein was able to utilize the U.S. financial system to make thousands of suspicious wire transfers and cash withdrawals for the apparent purpose of trafficking women and girls.”

He told Blanche that the document would help him continue his own congressional probe as ranking member of the Senate Finance Committee.

“In order to assist my investigation into this matter, I demand you immediately authorize the release," Wyden said.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference

Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference

The post Michael Saylor Pushes Digital Capital Narrative At Bitcoin Treasuries Unconference appeared on BitcoinEthereumNews.com. The suitcoiners are in town.  From a low-key, circular podium in the middle of a lavish New York City event hall, Strategy executive chairman Michael Saylor took the mic and opened the Bitcoin Treasuries Unconference event. He joked awkwardly about the orange ties, dresses, caps and other merch to the (mostly male) audience of who’s-who in the bitcoin treasury company world.  Once he got onto the regular beat, it was much of the same: calm and relaxed, speaking freely and with confidence, his keynote was heavy on the metaphors and larger historical stories. Treasury companies are like Rockefeller’s Standard Oil in its early years, Michael Saylor said: We’ve just discovered crude oil and now we’re making sense of the myriad ways in which we can use it — the automobile revolution and jet fuel is still well ahead of us.  Established, trillion-dollar companies not using AI because of “security concerns” make them slow and stupid — just like companies and individuals rejecting digital assets now make them poor and weak.  “I’d like to think that we understood our business five years ago; we didn’t.”  We went from a defensive investment into bitcoin, Saylor said, to opportunistic, to strategic, and finally transformational; “only then did we realize that we were different.” Michael Saylor: You Come Into My Financial History House?! Jokes aside, Michael Saylor is very welcome to the warm waters of our financial past. He acquitted himself honorably by invoking the British Consol — though mispronouncing it, and misdating it to the 1780s; Pelham’s consolidation of debts happened in the 1750s and perpetual government debt existed well before then — and comparing it to the gold standard and the future of bitcoin. He’s right that Strategy’s STRC product in many ways imitates the consols; irredeemable, perpetual debt, issued at par, with…
Share
BitcoinEthereumNews2025/09/18 02:12
Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent?

Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent?

The post Trump White House Registers Aliens.gov—Is the UFO File Drop Imminent? appeared on BitcoinEthereumNews.com. In brief The White House registered aliens.gov
Share
BitcoinEthereumNews2026/03/19 05:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26